世界の局所鎮痛剤市場見通し2028

【英語タイトル】Global Topical Pain Relief Market Outlook 2028

Research Nesterが出版した調査資料(NEST20JN029)・商品コード:NEST20JN029
・発行会社(調査会社):Research Nester
・発行日:2020年5月
・ページ数:175
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,150 ⇒換算¥444,050見積依頼/購入/質問フォーム
Site License(同一拠点閲覧用)USD5,150 ⇒換算¥551,050見積依頼/購入/質問フォーム
Enterprisewide License(同一法人閲覧用)USD7,150 ⇒換算¥765,050見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Global Topical Pain Relief Market Analysis 2020-2028Topical pain relief market comprises of opioid and non-opioid analgesics that are offered as creams, foams, gels, lotions, ointments and others. These analgesics are applied to body surfaces such as the skin or mucous membranes to treat painful ailments. Topical pain relief offers high concentrations of drug in peripheral effector sites, as opposed to the low serum levels of those sites on the back of which undesirable side effects are much lower on topical analgesic application. The global topical pain relief market is anticipated to achieve a CAGR of 4.31% over the forecast period, i.e. 2021-2028. Factors such as increasing investments from leading pharmaceutical companies as well as government organizations for R&D activities, increasing elderly population, growing prevalence of musculoskeletal disorders, such as osteoarthritis and autoimmune arthritis along with the growing technological advancements pertaining to the development of transdermal patches for pain management are anticipated to contribute significantly towards the growth of the global topical pain relief market. Additionally, growing popularity of topical as well as transdermal creams and patches among the sportspersons and the growing concern for arthritis, especially osteoarthritis are some of the factors anticipated to drive the growth of the global topical pain relief market.
The global topical pain relief market consists of various segments that are segmented by therapeutic class, formulation, distribution channel and by region. The formulation segment is further sub-divided into cream & rubs, patch, spray, gel and others. Out of these, the cream & rubs segment held a value of USD 2521.95 million in the year 2019 and is anticipated to reach a value of USD 3581.22 million by the end of 2028 by growing at a CAGR of 4.10% over the forecast period.
Based on region, the global topical pain relief market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Asia Pacific, which had accounted for 20.21% share in the year 2019, is estimated to witness the highest CAGR of 5.02% over the forecast period and cross a value of USD 2392.52 by the end of 2028.
Some of the affluent industry leaders in the global topical pain relief market are Reckitt Benckiser Group plc, Teikoku Pharma USA, Inc., Topical BioMedics, Inc., Sun Pharmaceutical Industries Ltd., AdvaCare Pharma®, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc. and GlaxoSmithKline plc.

【レポートの目次】

Global Topical Pain Relief Market
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Assumptions and Abbreviations
3. Research Methodology
3.1. Research Process
3.2. Secondary Research
3.3. Primary Research
3.4. Market Size Estimation
4. Executive Summary – Global Topical Pain Relief Market
5. Regulatory Landscape
6. Patent Analysis
7. Clinical Trial Analysis
8. Pipeline Analysis
9. Market Dynamics
9.1. Drivers
9.2. Restraints
9.3. Trends
9.4. Opportunities

10. Topical Pain Relief Market – Risk Analysis
10.1. Demand Risk Analysis
10.2. Supply Risk Analysis
11. Global Topical Pain Relief Market Outlook
11.1. Market Size and Forecast, 2018-2027F – By Value (USD Million)
11.1.1. By Therapeutic Class, 2019-2028F (USD MILLION)
11.1.1.1. Non-Opioids, 2019-2028F (USD MILLION)
11.1.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
11.1.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)
11.1.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
11.1.1.1.1.3. Others, 2019-2028F (USD MILLION)
11.1.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
11.1.1.1.3. Others, 2019-2028F (USD MILLION)
11.1.1.2. Opioids, 2019-2028F (USD MILLION)
11.1.2. By Type, 2019-2028F (USD MILLION)
11.1.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
11.1.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
11.1.3. By Formulation, 2019-2028F (USD MILLION)
11.1.3.1. Cream & Rubs, 2019-2028F (USD MILLION)

11.1.3.2. Patch, 2019-2028F (USD MILLION)
11.1.3.3. Spray, 2019-2028F (USD MILLION)
11.1.3.4. Gel, 2019-2028F (USD MILLION)
11.1.3.5. Others, 2019-2028F (USD MILLION)
11.1.4. By Distribution Channel, 2019-2028F (USD MILLION)
11.1.4.1. Online, 2019-2028F (USD MILLION)
11.1.4.2. Offline, 2019-2028F (USD MILLION)
11.1.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
11.1.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
11.1.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)
11.1.4.2.4. Others, 2019-2028F (USD MILLION)
11.1.5. By Region
11.1.5.1. North America, Europe, Asia Pacific, Latin America, Middle East & Africa
12. North America Topical Pain Relief Market Outlook
12.1. Macro-Economic Indicators impacting the North America Topical Pain Relief Market
12.2. Market Size & Forecast (USD Million)
12.2.1. By Therapeutic Class, 2019-2028F (USD MILLION)
12.2.1.1. Non-Opioids, 2019-2028F (USD MILLION)
12.2.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
12.2.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)

12.2.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
12.2.1.1.1.3. Others, 2019-2028F (USD MILLION)
12.2.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
12.2.1.1.3. Others, 2019-2028F (USD MILLION)
12.2.1.2. Opioids, 2019-2028F (USD MILLION)
12.2.2. By Type, 2019-2028F (USD MILLION)
12.2.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
12.2.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
12.2.3. By Formulation, 2019-2028F (USD MILLION)
12.2.3.1. Cream & Rubs, 2019-2028F (USD MILLION)
12.2.3.2. Patch, 2019-2028F (USD MILLION)
12.2.3.3. Spray, 2019-2028F (USD MILLION)
12.2.3.4. Gel, 2019-2028F (USD MILLION)
12.2.3.5. Others, 2019-2028F (USD MILLION)
12.2.4. By Distribution Channel, 2019-2028F (USD MILLION)
12.2.4.1. Online, 2019-2028F (USD MILLION)
12.2.4.2. Offline, 2019-2028F (USD MILLION)
12.2.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
12.2.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
12.2.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)

12.2.4.2.4. Others, 2019-2028F (USD MILLION)
12.2.5. By Country, 2019-2028F (USD MILLION)
12.2.5.1. US, 2019-2028F (USD MILLION)
12.2.5.2. Canada, 2019-2028F (USD MILLION)
13. Europe Topical Pain Relief Market Outlook
13.1. Macro-Economic Indicators impacting the Europe Topical Pain Relief Market
13.2. Market Size & Forecast (USD Million)
13.2.1. By Therapeutic Class, 2019-2028F (USD MILLION)
13.2.1.1. Non-Opioids, 2019-2028F (USD MILLION)
13.2.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
13.2.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)
13.2.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
13.2.1.1.1.3. Others, 2019-2028F (USD MILLION)
13.2.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
13.2.1.1.3. Others, 2019-2028F (USD MILLION)
13.2.1.2. Opioids, 2019-2028F (USD MILLION)
13.2.2. By Type, 2019-2028F (USD MILLION)
13.2.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
13.2.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
13.2.3. By Formulation, 2019-2028F (USD MILLION)

13.2.3.1. Cream & Rubs, 2019-2028F (USD MILLION)
13.2.3.2. Patch, 2019-2028F (USD MILLION)
13.2.3.3. Spray, 2019-2028F (USD MILLION)
13.2.3.4. Gel, 2019-2028F (USD MILLION)
13.2.3.5. Others, 2019-2028F (USD MILLION)
13.2.4. By Distribution Channel, 2019-2028F (USD MILLION)
13.2.4.1. Online, 2019-2028F (USD MILLION)
13.2.4.2. Offline, 2019-2028F (USD MILLION)
13.2.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
13.2.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
13.2.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)
13.2.4.2.4. Others, 2019-2028F (USD MILLION)
13.2.5. By Country, 2019-2028F (USD MILLION)
13.2.5.1. UK, 2019-2028F (USD MILLION)
13.2.5.2. Germany, 2019-2028F (USD MILLION)
13.2.5.3. Italy, 2019-2028F (USD MILLION)
13.2.5.4. France, 2019-2028F (USD MILLION)
13.2.5.5. Spain, 2019-2028F (USD MILLION)
13.2.5.6. Turkey, 2019-2028F (USD MILLION)
13.2.5.7. Russia, 2019-2028F (USD MILLION)
13.2.5.8. Rest of Europe, 2019-2028F (USD MILLION)
14. Asia Pacific Topical Pain Relief Market Outlook
14.1. Macro-Economic Indicators impacting the Asia Pacific Topical Pain Relief Market
14.2. Market Size & Forecast (USD Million)
14.2.1. By Therapeutic Class, 2019-2028F (USD MILLION)
14.2.1.1. Non-Opioids, 2019-2028F (USD MILLION)
14.2.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
14.2.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)
14.2.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
14.2.1.1.1.3. Others, 2019-2028F (USD MILLION)
14.2.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
14.2.1.1.3. Others, 2019-2028F (USD MILLION)
14.2.1.2. Opioids, 2019-2028F (USD MILLION)
14.2.2. By Type, 2019-2028F (USD MILLION)
14.2.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
14.2.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
14.2.3. By Formulation, 2019-2028F (USD MILLION)
14.2.3.1. Cream & Rubs, 2019-2028F (USD MILLION)
14.2.3.2. Patch, 2019-2028F (USD MILLION)
14.2.3.3. Spray, 2019-2028F (USD MILLION)

14.2.3.4. Gel, 2019-2028F (USD MILLION)
14.2.3.5. Others, 2019-2028F (USD MILLION)
14.2.4. By Distribution Channel, 2019-2028F (USD MILLION)
14.2.4.1. Online, 2019-2028F (USD MILLION)
14.2.4.2. Offline, 2019-2028F (USD MILLION)
14.2.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
14.2.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
14.2.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)
14.2.4.2.4. Others, 2019-2028F (USD MILLION)
14.2.5. By Country, 2019-2028F (USD MILLION)
14.2.5.1. China, 2019-2028F (USD MILLION)
14.2.5.2. India, 2019-2028F (USD MILLION)
14.2.5.3. Japan, 2019-2028F (USD MILLION)
14.2.5.4. South Korea, 2019-2028F (USD MILLION)
14.2.5.5. Australia, 2019-2028F (USD MILLION)
14.2.5.6. Rest of Asia Pacific, 2019-2028F (USD MILLION)
15. Latin America Topical Pain Relief Market Outlook
15.1. Macro-Economic Indicators impacting the Latin America Topical Pain Relief Market
15.2. Market Size & Forecast (USD Million)
15.2.1. By Therapeutic Class, 2019-2028F (USD MILLION)

15.2.1.1. Non-Opioids, 2019-2028F (USD MILLION)
15.2.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
15.2.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)
15.2.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
15.2.1.1.1.3. Others, 2019-2028F (USD MILLION)
15.2.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
15.2.1.1.3. Others, 2019-2028F (USD MILLION)
15.2.1.2. Opioids, 2019-2028F (USD MILLION)
15.2.2. By Type, 2019-2028F (USD MILLION)
15.2.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
15.2.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
15.2.3. By Formulation, 2019-2028F (USD MILLION)
15.2.3.1. Cream & Rubs, 2019-2028F (USD MILLION)
15.2.3.2. Patch, 2019-2028F (USD MILLION)
15.2.3.3. Spray, 2019-2028F (USD MILLION)
15.2.3.4. Gel, 2019-2028F (USD MILLION)
15.2.3.5. Others, 2019-2028F (USD MILLION)
15.2.4. By Distribution Channel, 2019-2028F (USD MILLION)
15.2.4.1. Online, 2019-2028F (USD MILLION)
15.2.4.2. Offline, 2019-2028F (USD MILLION)

15.2.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
15.2.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
15.2.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)
15.2.4.2.4. Others, 2019-2028F (USD MILLION)
15.2.5. By Country, 2019-2028F (USD MILLION)
15.2.5.1. Brazil, 2019-2028F (USD MILLION)
15.2.5.2. Mexico, 2019-2028F (USD MILLION)
15.2.5.3. Rest of Latin America, 2019-2028F (USD MILLION)
16. Middle East & Africa Topical Pain Relief Market Outlook
16.1. Macro-Economic Indicators impacting the Middle East & Africa Topical Pain Relief Market
16.2. Market Size & Forecast (USD Million)
16.2.1. By Therapeutic Class, 2019-2028F (USD MILLION)
16.2.1.1. Non-Opioids, 2019-2028F (USD MILLION)
16.2.1.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS), 2019-2028F (USD MILLION)
16.2.1.1.1.1. Capsaicin, 2019-2028F (USD MILLION)
16.2.1.1.1.2. Methyl Salicylates, 2019-2028F (USD MILLION)
16.2.1.1.1.3. Others, 2019-2028F (USD MILLION)
16.2.1.1.2. Lidocaine, 2019-2028F (USD MILLION)
16.2.1.1.3. Others, 2019-2028F (USD MILLION)
16.2.1.2. Opioids, 2019-2028F (USD MILLION)

16.2.2. By Type, 2019-2028F (USD MILLION)
16.2.2.1. Prescription Pain Relief, 2019-2028F (USD MILLION)
16.2.2.2. Over-the-counter Pain Relief, 2019-2028F (USD MILLION)
16.2.3. By Formulation, 2019-2028F (USD MILLION)
16.2.3.1. Cream & Rubs, 2019-2028F (USD MILLION)
16.2.3.2. Patch, 2019-2028F (USD MILLION)
16.2.3.3. Spray, 2019-2028F (USD MILLION)
16.2.3.4. Gel, 2019-2028F (USD MILLION)
16.2.3.5. Others, 2019-2028F (USD MILLION)
16.2.4. By Distribution Channel, 2019-2028F (USD MILLION)
16.2.4.1. Online, 2019-2028F (USD MILLION)
16.2.4.2. Offline, 2019-2028F (USD MILLION)
16.2.4.2.1. Pharmacies, 2019-2028F (USD MILLION)
16.2.4.2.2. Retail Stores, 2019-2028F (USD MILLION)
16.2.4.2.3. Hypermarkets/Supermarkets, 2019-2028F (USD MILLION)
16.2.4.2.4. Others, 2019-2028F (USD MILLION)
16.2.5. By Country, 2019-2028F (USD MILLION)
16.2.5.1. Israel, 2019-2028F (USD MILLION)
16.2.5.2. Saudi Arabia, 2019-2028F (USD MILLION)
16.2.5.3. UAE, 2019-2028F (USD MILLION)

16.2.5.4. South Africa, 2019-2028F (USD MILLION)
16.2.5.5. Rest of Middle East & Africa, 2019-2028F (USD MILLION)
17. Competitive Landscape
· Topical BioMedics
· Reckitt Benckiser Group plc.
· Sun Pharmaceutical Industries Ltd.
· AdvaCare Pharma
· Teikoku Pharma USA, Inc.
· Sanofi
· Johnson and Johnson
· Novartis
· Pfizer Inc.
· GlaxoSmithKline plc
18. Strategic Recommendations



★調査レポート[世界の局所鎮痛剤市場見通し2028] (コード:NEST20JN029)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の局所鎮痛剤市場見通し2028]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆